Arcutis Biotherapeutics ARQT Cash Flow Statement (2019-2026)

NASDAQ ARQT
$23.90 +0.24 (+1.01%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Arcutis Biotherapeutics Quarterly Cash Flow Statement

Periods 30 quarters
Latest Jun 2026

Arcutis Biotherapeutics reported cash from operations of $12.64M and free cash flow of $12.64M for the quarter ended Jun 2026. This cash flow statement covers 30 quarters of results from Mar 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-57.06M-71.52M-65.23M-68.06M-107.71M-72.02M-80.10M-70.99M-44.77M-66.28M-35.38M-52.33M-41.54M-10.79M-25.06M-15.89M7.41M17.37M-11.29M15.01M
Share-based CompensationStock Comp.
5.36M5.69M6.53M8.10M8.79M9.26M9.48M10.58M10.00M8.76M10.03M12.52M9.78M9.39M9.78M10.49M10.04M10.06M10.69M12.76M
Cash from OperationsCash from Ops.
-40.88M-51.71M-56.98M-61.98M-67.69M-71.06M-80.34M-66.48M-43.98M-56.24M-31.60M-45.12M-34.69M-0.75M-30.38M0.32M-1.75M26.18M2.24M12.64M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
-1.15M-0.89M-0.62M-0.27M1.13M2.02M2.16M1.82M1.53M1.47M1.73M2.39M1.69M1.10M0.86M0.69M0.55M-0.01M0.18M0.22M
Amortization of Deferred ChargesAmort. Deferred Charges
0.39M0.40M0.80M
Change in Working Capital
Change in ReceivablesChange Receivables
2.43M6.03M4.31M4.44M2.21M6.39M11.35M5.18M16.61M14.13M12.35M21.27M8.43M31.11M-1.85M10.79M
Change in InventoryChange Inventory
4.31M3.21M1.04M1.92M3.44M-0.78M0.11M0.63M-0.61M0.27M1.95M-0.52M5.89M0.01M14.58M1.18M
Change in Account PayablesChange Payables
2.24M2.39M5.20M-4.03M0.22M0.18M3.38M4.94M-3.97M-1.19M0.99M-5.16M6.51M-0.10M0.31M0.55M-9.29M6.73M5.61M-11.54M
Change in Accured ExpensesChange Accured Exp.
3.37M11.68M-5.53M-1.51M7.62M0.62M-4.46M-5.07M9.20M5.92M-0.33M9.06M10.12M13.18M-0.21M21.23M5.57M23.45M20.77M9.96M
Investing Activities
Capital ExpendituresCapex
0.14M0.26M0.12M0.08M0.01M0.12M0.08M0.28M0.06M0.01M0.14M0.61M0.08M0.16M
Change in Acquisitions & DivestmentsChange Acquisitions
36.00M72.00M70.92M132.89M67.25M80.41M147.50M135.00M68.00M56.00M77.25M63.64M90.61M57.28M68.47M60.65M43.30M55.00M50.82M50.52M
Cash from Investing ActivitiesCash from Investing
3.47M23.50M15.30M52.56M-197.26M42.20M107.75M89.12M45.55M-62.19M-28.70M-62.14M84.78M34.88M11.75M17.42M-25.25M-34.18M-11.33M-15.22M
Financing Activities
Other financing activitiesOther financing
0.06M0.17M0.26M0.71M0.02M0.92M0.10M0.89M0.05M0.21M0.08M0.81M0.39M1.52M0.40M0.92M0.61M2.67M1.07M1.36M
Cash from Financing ActivitiesCash from Financing
0.06M72.88M14.72M1.13M284.99M0.96M0.10M1.07M0.87M99.29M161.76M1.46M0.39M-97.41M0.40M1.38M1.48M3.72M1.07M1.99M
Change in Capital Stock
Net Equity Issued and RepurchasedNet Equity Issued
14.50M-0.04M3.10M161.68M3.10M
Additional items
Exchange Rate EffectFX Effect
-0.05M0.01M-0.07M0.07M-0.07M-0.03M0.10M-0.23M0.00M0.20M-0.10M0.06M-0.12M-0.05M
Change in Cash
-37.35M44.67M-26.96M-8.28M20.03M-27.90M27.45M23.71M2.36M-19.07M101.39M-105.83M50.58M-63.52M-18.23M19.33M-25.62M-4.21M-8.14M-0.64M
Free Cash FlowFCF
-41.02M-51.97M-57.10M-62.06M-67.70M-71.19M-80.43M-66.76M-44.05M-56.25M-31.60M-45.12M-34.83M-0.75M-30.99M0.25M-1.75M26.18M2.08M12.64M
Net Cash FlowNCF
-37.35M44.67M-26.96M-8.28M20.03M-27.90M27.51M23.70M2.43M-19.14M101.46M-105.80M50.48M-63.28M-18.23M19.13M-25.52M-4.27M-8.03M-0.59M